The Safety and Efficacy of Umbilical Cord Blood Mononuclear Cells in Patients With Secondary Poor Graft Function After Hematopoietic Stem Cell Transplantation

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

February 29, 2028

Conditions
Poor Graft Function
Interventions
BIOLOGICAL

Dose escalation

"Three dose groups are preset. The doses are 2.0×10\^6/kg/time, 3.5×10\^6/kg/time and 5.0×10\^6/kg/ time respectively, in accordance with the 3+3 dose escalation principle, and proceed in turn.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."

BIOLOGICAL

Dose extension

"According to the safety data of dose escalation stage, one dose group is selected for extension.~Each subject receives conventional treatment plus umbilical cord blood mononuclear cells therapy, with 4 consecutive intravenous infusions of umbilical cord blood mononuclear cells at 1 week intervals."

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, China, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER